section name header

Basics

Key Differences Between Adult-Onset Dermatomyositis and JDM

  • JDM is rarely paraneoplastic.

  • Children tend to have more severe muscle inflammation.

  • Calcinosis cutis occurs more frequently in JDM.

  • JDM is associated with lower mortality.

  • Adults have higher frequency of myositis-specific antibodies

Pathogenesis

Clinical Manifestations

Diagnosis

Management-icon.jpg Management

  • The course of JDM is variable and can be chronic in up to 60% of cases.

  • Limited skin disease and short duration of disease before treatment is initiated portends a better prognosis.

  • First-line treatment is high-dose systemic corticosteroids preferably given IV, as pulses, every 1 to 2 days until muscle enzymes normalize.

  • Methotrexate in addition to systemic steroids is more effective than either treatment alone.

  • Methotrexate alone is second-line treatment when corticosteroids cannot be given.

  • Other systemic agents that have shown efficacy for JDM include the following:

    • IVIG

    • Azathioprine

    • Cyclosporine

    • Rituximab

  • Skin disease may persist despite improvement in muscle disease.

  • In general, patients should avoid excessive sun exposure and use broad-spectrum sunscreens.

  • The antimalarial, hydroxychloroquine (Plaquenil), 5 mg/kg/day can help the cutaneous manifestations.

  • Topical corticosteroids may help with itching but do little to improve the skin changes associated with JDM.

  • Calcinosis cutis is difficult to treat and can lead to significant morbidity.

  • The bisphosphonates and surgical excision have both been helpful for problematic calcinosis.

Helpful-Hint-icon.jpg Helpful Hint

  • Patients on hydroxychloroquine long term should have regular ophthalmologic examinations every 6 months.

Point-Remember-icon.jpg Points to Remember

  • Sun exposure is known to trigger both cutaneous and muscle signs.

  • Presence of periungual telangiectasias and erythema on the skin correlates with disease activity.